Citing “imminent data” from its COVID-19 trial and
an autoimmune disorder study, Raymond James’ Steven Seedhouse has
upgraded InflaRx (NASDAQ:IFRX) to Outperform with a $10 (85% upside) price target.
Preliminary data from the 30-patient study
assessing IFX-1 in patients with severe COVID-19-induced pneumonia
should be available this quarter.
Initial data on its ongoing study testing IFX-1 in
a rare autoimmune disease called AAV should be available “soon” since
enrollment was stopped at 19 due to pandemic disruptions.
https://seekingalpha.com/news/3566905-inflarx-up-11-premarket-on-bullish-call-raymond-james
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.